792970-55-9 Usage
General Description
1-(tert-Butoxycarbonyl)-3-(dimethylamino)azetidine, also known as Boc-DMAZ, is a chemical compound with the molecular formula C11H20N2O2. It is a derivative of azetidines and is commonly used as a building block in organic synthesis and pharmaceutical research. Boc-DMAZ is a stable compound that can be easily handled and stored, making it a valuable tool for the development of new drugs and materials. Its unique structure and properties make it a versatile reagent for the preparation of various functionalized azetidine derivatives, which have potential applications in medicinal chemistry and chemical biology. Due to its utility in drug discovery and development, Boc-DMAZ is a widely studied and utilized compound in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 792970-55-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,2,9,7 and 0 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 792970-55:
(8*7)+(7*9)+(6*2)+(5*9)+(4*7)+(3*0)+(2*5)+(1*5)=219
219 % 10 = 9
So 792970-55-9 is a valid CAS Registry Number.
792970-55-9Relevant articles and documents
KRAS G12C INHIBITORS
-
Paragraph 0384, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF
-
Paragraph 0145; 0146, (2017/06/19)
The present invention relates to a 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description for details.
As the NS4B inhibitor benzofuran analogs (by machine translation)
-
Paragraph 0378; 0380; 0381; 0382; 0383, (2016/10/31)
The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)
